Adlai Nortye (NASDAQ:ANL) Shares Gap Down – What’s Next?

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL)’s stock price gapped down before the market opened on Monday. The stock had previously closed at $10.28, but opened at $9.85. Adlai Nortye shares last traded at $10.8290, with a volume of 20,890 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have issued reports on ANL. Wall Street Zen lowered shares of Adlai Nortye from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a research report on Monday, October 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research note on Monday, October 12th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a report on Tuesday, September 8th. Finally, Loop Capital set a $49.00 price objective on Adlai Nortye in a research report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Adlai Nortye Price Performance

The company’s 50-day moving average is $13.37 and its 200-day moving average is $11.46.

Insider Activity at Adlai Nortye

In related news, CFO Xiaofeng Ye sold 5,667 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $14.25, for a total transaction of $80,754.75. Following the completion of the transaction, the chief financial officer owned 147,757 shares in the company, valued at $2,105,537.25. This trade represents a 3.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total value of $159,900.00. Following the completion of the sale, the director owned 121,453 shares in the company, valued at $1,942,033.47. This trade represents a 7.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 26,881 shares of company stock worth $411,060.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ANL. Braidwell LP acquired a new position in Adlai Nortye in the second quarter valued at about $9,145,000. Boone Capital Management LLC acquired a new position in shares of Adlai Nortye in the 2nd quarter worth approximately $2,971,000. Affinity Asset Advisors LLC bought a new stake in Adlai Nortye during the 1st quarter worth approximately $1,140,000. ADAR1 Capital Management LLC bought a new stake in Adlai Nortye during the 1st quarter worth approximately $816,000. Finally, Seven Fleet Capital Management LP bought a new stake in Adlai Nortye during the 2nd quarter worth approximately $1,302,000. 35.21% of the stock is owned by institutional investors.

About Adlai Nortye

Adlai Nortye (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research is centered on treatments designed to stimulate or enhance the immune system’s ability to identify and attack cancer cells.

Adlai Nortye’s pipeline includes buparlisib, an oral pan-class I phosphoinositide 3-kinase inhibitor being investigated in oncology. The company has evaluated buparlisib in combination with immunotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.